Boehringer Ingelheim advances the collaboration with Inventiva

| By | Boehringer Ingelheim, Drug Development

Inventiva, a French biopharmaceutical company developing innovative therapies, particularly for the treatment of fibrotic diseases, today announced the exercise of an option by Boehringer Ingelheim advancing the collaboration, which began in May 2016.

The joint research team has validated a new fibrosis target and data generated in the program supports its therapeutic potential in fibrotic conditions and idiopathic pulmonary fibrosis (IPF) has been selected as the first indication to be investigated. Boehringer Ingelheim’s execution of this option triggers a milestone payment to Inventiva of €2,5 million.

“We are very pleased with this decision by Boehringer Ingelheim, which underscores the research capabilities developed by Inventiva in fibrosis, and excited to develop this new IPF approach with Boehringer Ingelheim, a partner offering the research, development, and commercial expertise needed to develop breakthrough therapies for patients suffering from fibrotic diseases such as IPF,” said Pierre Broqua, Ph.D., Chief Scientific Officer and Co-Founder of Inventiva.

“We are excited about moving this very productive and highly interactive collaboration forward, which combines Inventiva’s strong competency and know-how in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s expertise in the discovery and development of treatments for fibrotic diseases like IPF,” said Clive R. Wood, Ph.D., Senior Corporate Vice President Discovery Research at Boehringer Ingelheim “This collaboration with Inventiva is part of Boehringer Ingelheim’s comprehensive research and development focus on fibrotic diseases.”

In May 2016, Inventiva and Boehringer Ingelheim entered into a multi-year research and development partnership. Under the terms of the agreement, Inventiva and Boehringer Ingelheim will jointly validate a newly selected target, which potentially addresses a central mechanism driving the pathogenesis of IPF. Inventiva is eligible to receive research funding, milestone payments of up to €170 million, and tiered royalty payments for any commercial product resulting from the collaboration.

Inventiva will use its fibrosis target-validation platform to study the mechanism of action of the target in several organs and provide data particularly derived from IPF patient cells which Inventiva has available in-house. Inventiva also contributes its expertise in drug discovery and a substantial collection of proprietary small molecule modulators of the target class. The drug discovery program will be jointly conducted by Inventiva and Boehringer Ingelheim teams, with the latter to take full responsibility of the preclinical and clinical development and commercialization of clinical candidates.

SOURCE: inventiva
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.